MA45843B1 - Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) - Google Patents
Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)Info
- Publication number
- MA45843B1 MA45843B1 MA45843A MA45843A MA45843B1 MA 45843 B1 MA45843 B1 MA 45843B1 MA 45843 A MA45843 A MA 45843A MA 45843 A MA45843 A MA 45843A MA 45843 B1 MA45843 B1 MA 45843B1
- Authority
- MA
- Morocco
- Prior art keywords
- ghrelin
- goat
- acyl transferase
- transferase inhibitors
- derivatives used
- Prior art date
Links
- 241000283707 Capra Species 0.000 title abstract 2
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title abstract 2
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title abstract 2
- 239000002404 acyltransferase inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical class C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés de formule générale (i) dans lesquels les groupes r1, r2 et n sont tels que définis dans la revendication 1, qui ont des propriétés pharmacologiques valorisables, en particulier, qui se lient au ghréline o-acyl transférase (chèvre) et modulent son activité. Ces composés conviennent pour traiter et prévenir des maladies pouvant être influencées par ce récepteur, telles que des maladies métaboliques, en particulier l'obésité
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16183047 | 2016-08-05 | ||
| PCT/EP2017/069274 WO2018024653A1 (fr) | 2016-08-05 | 2017-07-31 | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45843A MA45843A (fr) | 2019-06-12 |
| MA45843B1 true MA45843B1 (fr) | 2021-06-30 |
Family
ID=56609762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45843A MA45843B1 (fr) | 2016-08-05 | 2017-07-31 | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9994591B2 (fr) |
| EP (1) | EP3494120B1 (fr) |
| JP (1) | JP6651054B2 (fr) |
| KR (1) | KR102496075B1 (fr) |
| CN (1) | CN109843891B (fr) |
| AR (1) | AR109296A1 (fr) |
| AU (1) | AU2017307033B2 (fr) |
| CL (1) | CL2019000274A1 (fr) |
| CO (1) | CO2019000601A2 (fr) |
| CY (1) | CY1124381T1 (fr) |
| DK (1) | DK3494120T3 (fr) |
| EA (1) | EA037277B1 (fr) |
| ES (1) | ES2874587T3 (fr) |
| HR (1) | HRP20210908T1 (fr) |
| HU (1) | HUE054928T2 (fr) |
| IL (1) | IL264506B (fr) |
| LT (1) | LT3494120T (fr) |
| MA (1) | MA45843B1 (fr) |
| MX (1) | MX384847B (fr) |
| MY (1) | MY197064A (fr) |
| PE (1) | PE20190414A1 (fr) |
| PH (1) | PH12019500254A1 (fr) |
| PL (1) | PL3494120T3 (fr) |
| PT (1) | PT3494120T (fr) |
| RS (1) | RS61937B1 (fr) |
| SA (1) | SA519401039B1 (fr) |
| SG (1) | SG11201811804QA (fr) |
| SI (1) | SI3494120T1 (fr) |
| TW (1) | TWI749042B (fr) |
| UA (1) | UA124267C2 (fr) |
| WO (1) | WO2018024653A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200187A1 (ar) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
| CN111655700B (zh) * | 2018-02-02 | 2023-07-18 | 勃林格殷格翰国际有限公司 | 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物 |
| CN111630055B (zh) * | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物 |
| MX2020008116A (es) * | 2018-02-02 | 2020-09-25 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| CA3173731A1 (fr) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Agonistes de gpr40 |
| PL4153600T3 (pl) | 2020-05-22 | 2024-12-16 | Boehringer Ingelheim International Gmbh | Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu |
| EP4153599B1 (fr) | 2020-05-22 | 2024-03-13 | Boehringer Ingelheim International GmbH | Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle |
| CN112014340A (zh) * | 2020-09-01 | 2020-12-01 | 广西玮美生物科技有限公司 | 非人灵长类动物胃饥饿素的检测方法 |
| CN118652261B (zh) * | 2024-05-29 | 2025-02-07 | 南京理工大学 | 一种耐热荧光活性含能化合物及其合成方法 |
| US20260083736A1 (en) | 2024-09-24 | 2026-03-26 | Boehringer Ingelheim International Gmbh | Ghrelin o-acyl transferase (goat) inhibitors for use in the treatment of substance use disorder in patients with high impulsivity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| CL2007003580A1 (es) | 2006-12-11 | 2009-03-27 | Boehringer Ingelheim Int | Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes. |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| PL2370462T3 (pl) | 2008-12-15 | 2015-01-30 | Zealand Pharma As | Analogi glukagonu |
| AU2008365557A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| KR20130086343A (ko) | 2010-06-24 | 2013-08-01 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| KR20140114845A (ko) | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| US9238639B2 (en) * | 2012-02-24 | 2016-01-19 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (fr) * | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Petits inhibiteurs lipopeptidomimétiques de la ghréline o-acyl transférase |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| CN111630055B (zh) * | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物 |
| CN111655700B (zh) | 2018-02-02 | 2023-07-18 | 勃林格殷格翰国际有限公司 | 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物 |
| JOP20200187A1 (ar) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
| MX2020008116A (es) | 2018-02-02 | 2020-09-25 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
-
2017
- 2017-07-31 RS RS20210702A patent/RS61937B1/sr unknown
- 2017-07-31 HR HRP20210908TT patent/HRP20210908T1/hr unknown
- 2017-07-31 MX MX2019001427A patent/MX384847B/es unknown
- 2017-07-31 JP JP2019506164A patent/JP6651054B2/ja active Active
- 2017-07-31 EA EA201990418A patent/EA037277B1/ru not_active IP Right Cessation
- 2017-07-31 ES ES17743064T patent/ES2874587T3/es active Active
- 2017-07-31 PT PT177430642T patent/PT3494120T/pt unknown
- 2017-07-31 DK DK17743064.2T patent/DK3494120T3/da active
- 2017-07-31 EP EP17743064.2A patent/EP3494120B1/fr active Active
- 2017-07-31 HU HUE17743064A patent/HUE054928T2/hu unknown
- 2017-07-31 LT LTEP17743064.2T patent/LT3494120T/lt unknown
- 2017-07-31 KR KR1020197006448A patent/KR102496075B1/ko active Active
- 2017-07-31 SG SG11201811804QA patent/SG11201811804QA/en unknown
- 2017-07-31 UA UAA201901840A patent/UA124267C2/uk unknown
- 2017-07-31 MA MA45843A patent/MA45843B1/fr unknown
- 2017-07-31 US US15/664,119 patent/US9994591B2/en active Active
- 2017-07-31 CN CN201780047100.1A patent/CN109843891B/zh active Active
- 2017-07-31 PL PL17743064T patent/PL3494120T3/pl unknown
- 2017-07-31 AU AU2017307033A patent/AU2017307033B2/en active Active
- 2017-07-31 PE PE2019000271A patent/PE20190414A1/es unknown
- 2017-07-31 SI SI201730770T patent/SI3494120T1/sl unknown
- 2017-07-31 WO PCT/EP2017/069274 patent/WO2018024653A1/fr not_active Ceased
- 2017-07-31 MY MYPI2018002719A patent/MY197064A/en unknown
- 2017-08-04 TW TW106126319A patent/TWI749042B/zh active
- 2017-08-04 AR ARP170102213A patent/AR109296A1/es active IP Right Grant
-
2018
- 2018-05-09 US US15/974,882 patent/US10308667B2/en not_active Ceased
-
2019
- 2019-01-22 CO CONC2019/0000601A patent/CO2019000601A2/es unknown
- 2019-01-28 IL IL264506A patent/IL264506B/en active IP Right Grant
- 2019-02-01 CL CL2019000274A patent/CL2019000274A1/es unknown
- 2019-02-05 SA SA519401039A patent/SA519401039B1/ar unknown
- 2019-02-06 PH PH12019500254A patent/PH12019500254A1/en unknown
-
2020
- 2020-10-14 US US17/069,940 patent/USRE49446E1/en active Active
-
2021
- 2021-06-14 CY CY20211100525T patent/CY1124381T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45843A (fr) | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) | |
| EA200801934A1 (ru) | 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2 | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
| EA201000331A1 (ru) | 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны | |
| EA201000314A1 (ru) | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны | |
| MA45153B1 (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| MA32654B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
| MA50398B1 (fr) | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma | |
| MA38170B1 (fr) | Nouveaux acides indanyloxydihydrobenzofuranylacétiques | |
| EA200700617A1 (ru) | Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| MA40993B1 (fr) | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 | |
| EA200901159A1 (ru) | Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она | |
| PH12020551170A1 (en) | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| MA34839B1 (fr) | Dihydrofuranes condensés en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles apparentes | |
| MA31623B1 (fr) | Nouveaux herbicides | |
| MX2020013699A (es) | Derivados de pirazol como inhibidores de malt1. | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MX2020008116A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). | |
| SA520412488B1 (ar) | مركبات لعلاج اضطرابات معتمدة على كيناز | |
| MX2020013899A (es) | Derivados de pirazol como inhibidores de malt1. |